News

DNA hypomethylation makes humans prone to diseases
Enlarge image

SciencePoland

DNA hypomethylation makes humans prone to diseases

22.05.2012 - A Polish-US research team has found that hypomethylation destablises DNA and boosts the risk of neurological diseases.

Warsaw/Houston –Bioinformaticians from Warsaw University and the Baylor College of Medicine have provided an explanation for how disease-associated mutation hotspots may arise. According to results of the group under Aleksandar Milosavljevic and Tomasz Gambin, regions on human chromosomes that carry only few so-called methylation marks show a tenfold higher number of structural mutations than the genome-wide average. Patients diagnosed with schizophrenia, bipolar disorder, developmental delay, and autism had a significant higher amount of such predetermined breaking points, (PloS Genetics 8(5): e1002692).

The researchers suggest that the amount of methylation might mediate genomic stability.  They compared methylome maps from human sperm cell samples with publicly available structural variation data. Their results points to a strong association of germline hypomethylation and genomic instability which might lead to new diagnostic and therapeutic approaches. "We have found that these rare and de novo structural variants, as well as changes of the human genome that have accumulated the fastest since the branching chimpanzee, are significantly concentrated within methylation deserts," senior author Aleksandar Milosavljevic, a molecular and human genetics researcher at Baylor College of Medicine, said in a statement.

Lack of methylation of genomic DNA has been previously associated with high structural mutability in gibbons and in human cancer cells, but the association with structural mutability in the human germline has not been explored prior to this study.

http://www.european-biotechnology-news.com/news/news/2012-02/dna-hypomethylation-makes-humans-prone-to-diseases.html

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE14.50 EUR9.19%
  • SARTORIUS143.75 EUR7.28%
  • FORMYCON31.50 EUR4.06%

FLOP

  • THERAMETRICS0.08 CHF-11.11%
  • CO.DON2.90 EUR-7.94%
  • 4SC1.25 EUR-6.72%

TOP

  • MEDIGENE14.50 EUR117.4%
  • 4SC1.25 EUR76.1%
  • FORMYCON31.50 EUR39.9%

FLOP

  • CYTOS1.27 CHF-15.3%
  • BB BIOTECH280.70 EUR-11.5%
  • MORPHOSYS62.50 EUR-10.2%

TOP

  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.27 CHF647.1%
  • FORMYCON31.50 EUR343.7%

FLOP

  • MOLOGEN5.02 EUR-53.5%
  • BIOFRONTERA2.60 EUR-20.2%
  • THERAMETRICS0.08 CHF-20.0%

No liability assumed, Date: 17.04.2015